AroCell AB (publ) announced that its recent study on different clinical applications of the TK 210 ELISA in ovarian cancer has been accepted for publication in the Karger Oncology journal. The study focused on demonstrating the clinical utility of TK1-specific activity (TK1 SA) in the early detection of ovarian cancer. This study was conducted in collaboration with Professor Josko Osredkar and is titled "Clinical Significance of the TK1 specific Activity in the Early Detection of Ovarian Cancer".

TK1 SA is determined by calculating the ratio of TK1 activity by TK-Liaison and TK1 protein by AroCell TK 210 ELISA. The study included 134 patients with ovarian tumors (72 benign and 62 malignant) and 64 healthy age-matched controls. The study results revealed that TK1 SA, which complements traditional biomarkers such as CA 125 and HE4, significantly improved the sensitivity for early detection of benign and malignant ovarian cancer.

The combination of various biomarkers provided a more comprehensive and accurate diagnostic approach. These findings have implications in proving the early detection rates and subsequent treatment outcomes for ovarian cancer patients. Furthermore, the study observed the fluctuations in TK1 SA levels in relation to surgery and Chemotherapy which provided valuable information for monitoring the effectiveness of treatment and assessing disease progression.